结构表面学揭示了一种AML特异性整合素β的构造,作为CAR T细胞治疗的点
Kamal Mandal1, Gianina Wicaksono1, Clinton Yu2
1Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Nature cancer
|October 31, 2023
概括
研究人员发现了一种新的方法,通过识别癌细胞表面的独特蛋白质结构来向癌细胞. 这种方法成功准了急性髓性白血病 (AML) 细胞,为癌症免疫治疗提供了一个有前途的新途径.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 扩展细胞疗法受到缺乏癌症特异性表面标记物的限制.
- 当前的目标发现方法往往错过了瘤细胞上独特的蛋白质构造.
研究的目的:
- 探索癌症特异性表面蛋白质构成作为免疫治疗点.
- 为确定这些目标,开发一种名为"结构表面经济学"的新战略.
- 为了验证这种方法在急性髓性白血病 (AML).
主要方法:
- 利用结构表面学,整合交联质谱和糖蛋白表面捕获.
- 将该技术应用于急性髓性白血病 (AML) 样本.
- 开发和特征复合抗体针对已识别的目标.
主要成果:
- 确定了整合素β2的激活构造作为AML的特定标.
- 证明了针对这种形状的仿真抗原受体T细胞可以消除AML细胞和患者衍生异体移植.
- 对正常的造血细胞没有显著的毒性.
结论:
- 根据蛋白质构成验证了一种新的AML特异性向抗原.
- 结构表面学为发现和准形状特异性抗原提供了一个强大的工具包.
- 这一策略有可能在癌症免疫治疗中得到更广泛的应用.
相关概念视频
Selectins
3.3K
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K
Immunoglobulin-like Cell Adhesion Molecules
3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Activation of Integrins
3.5K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.5K
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
